TrialCancer chemotherapy and pharmacology2022

Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.

Takafumi Ide et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.